Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 57-00-1
2. N-amidinosarcosine
3. Creatin
4. Kreatin
5. Krebiozon
6. N-methyl-n-guanylglycine
7. 2-(1-methylguanidino)acetic Acid
8. Methylglycocyamine
9. Glycine, N-(aminoiminomethyl)-n-methyl-
10. (alpha-methylguanido)acetic Acid
11. Creatine, Hydrate
12. Pyrolysate
13. N-carbamimidoyl-n-methylglycine
14. Methylguanidoacetic Acid
15. Cosmocair C 100
16. 2-(1-methylcarbamimidamido)acetic Acid
17. Creatine, Anhydrous
18. Kreatinum
19. Neotine
20. Alpha-methylguanidino Acetic Acid
21. 2-[carbamimidoyl(methyl)amino]acetic Acid
22. N-(aminoiminomethyl)-n-methylglycine
23. (.alpha.-methylguanido)acetic Acid
24. Nsc 8752
25. Nsc-8752
26. N-[(e)-amino(imino)methyl]-n-methylglycine
27. Ai3-15320
28. Chebi:16919
29. ((amino(imino)methyl)(methyl)amino)acetic Acid
30. Nsc8752
31. Mu72812gk0
32. (n-methylcarbamimidamido)acetic Acid
33. N-(aminoiminomethyl)-n-methyl-glycine
34. Creatine (8ci)
35. ((amino(imino)methyl)(methyl)amino)acetate
36. [[amino(imino)methyl](methyl)amino]acetate
37. [[amino(imino)methyl](methyl)amino]acetic Acid
38. Unii-mu72812gk0
39. A-meethyl Guanidine Acetic Acid
40. Hsdb 7336
41. Methylguanidoacetate
42. Iom
43. Einecs 200-306-6
44. Mfcd00004282
45. Creatine [hsdb]
46. Creatine [inci]
47. Creatine [ii]
48. Creatine [mi]
49. Creatine [vandf]
50. Bmse000078
51. Bmse000950
52. Bmse000999
53. Creatine [usp-rs]
54. Creatine [who-dd]
55. Ec 200-306-6
56. (alpha-methylguanido)acetate
57. (a-methylguanido)acetic Acid
58. Schembl21567
59. Creatine, Hydrate (salt/mix)
60. Chembl283800
61. Gtpl4496
62. Dtxsid1040451
63. Str05570
64. Zinc3861770
65. Bbl012187
66. Bdbm50357229
67. S5588
68. Stl163516
69. Akos005717096
70. 2-(n-methylcarbamimidamido)acetic Acid
71. Ccg-266112
72. Cs-w011104
73. Db00148
74. Hy-w010388
75. N-[amino(imino)methyl]-n-methylglycine
76. Creatine, Anhydrous, >=99.0% (nt)
77. 2-(carbamimidoyl-methyl-amino)acetic Acid
78. Ac-34370
79. C3610
80. Ft-0624083
81. (n-(amidino)-n-methylamino)acetic Acid
82. C00300
83. D89574
84. [[amino(imino)methyl](methyl)amino]acetic Acid #
85. Q223600
86. W-105270
87. F8880-7830
88. 1093737-19-9
| Molecular Weight | 131.13 g/mol |
|---|---|
| Molecular Formula | C4H9N3O2 |
| XLogP3 | -1.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 131.069476538 g/mol |
| Monoisotopic Mass | 131.069476538 g/mol |
| Topological Polar Surface Area | 90.4 Ų |
| Heavy Atom Count | 9 |
| Formal Charge | 0 |
| Complexity | 134 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Creatine, as well as a creatine analogue called cyclocreatine, inhibit growth of a broad range of solid tumors in rat models of cancer; these tumors express high levels of CK. Although the mechanism for tumor inhibition is unknown...
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
Phosphocreatine inhibits enzymes in the glycolitic pathway, including glyceraldehydes-3-phosphate dehydrogenase, phosphofructokinase and pyruvate kinase.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
Safety data are lacking and are urgently needed, especially for long-term use of creatine and for use among the pediatric population (including adolescence) and among those in poor health. There are some reports that long-term use of creatine may be nephrotoxic. This needs further investigation before long-term creatine supplementation can be recommended under any circumstance.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.116 (2001)
Creatine is contraindicated in those with renal failure and renal disorders such as nephritic syndrome.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.116 (2001)
Anecdotal reports of adverse events to FDA have included rash, dyspnea, vomiting, diarrhea, nervousness, anxiety, migraine, fatigue, polymyositis, myopathy,seizures and atrial fibrillation.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.117 (2001)
There are reports of elevated serum creatinine, a metabolite of creatine and a marker of kidney function, in some who take creatine and have normal renal function. This /effect on renal function tests/ is reversible upon discontinuation of creatine.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
For nutritional supplementation, also for treating dietary shortage or imbalance.
Creatine is a essential, non-proteinaceous amino acid derivative found in all animals. It is synthesized in the kidney, liver, and pancreas from L-arginine, glycine and L-methionine. Following its biosynthesis, creatine is transported to the skeletal muscle, heart, brain and other tissues. Most of the creatine is metabolized in these tissues to phosphocreatine (creatine phosphate). Phosphocreatine is a major energy storage form in the body. Supplemental creatine may have an energy-generating action during anaerobic exercise and may also have neuroprotective and cardioprotective actions.
In muscle and nerve, most of the creatine is phosphorylated to phosphocreatine (pCr) in a reaction that is catalyzed by the enezyme creatine kinase (CK), there are three isoforms of (isoenzymes) of CK. CK-MM is the skeletal muscle isoform; CK-BB, the brain isoform, and CK-MB, the isoform found in cardiac muscle. Most of the PCr in the body is in skeletal muscle.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
Creatine is absorbed from the small intestines and enters the portal circulation and is transported to the liver. The ingested creatine, and the creatine made in the liver, is then transported into the systemic circulation and distributed into various tissues of the body, including muscle and nerves, by crossing the cell membrane via a specific creatine-transported system against a 200:1 gradient.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
Within muscle and nerve cells, about 60 to 67% of the creatine entering the cells gets converted to phosphocreatine via the enzyme creatine kinase. About 2% of creatine is converted to creatinine, and both creatine and creatinine are excreted by the kidneys.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
3 hours
In the muscles, a fraction of the total creatine binds to phosphate - forming creatine phosphate. The reaction is catalysed by creatine kinase, and the result is phosphocreatine (PCr). Phosphocreatine binds with adenosine diphosphate to convert it back to ATP (adenosine triphosphate), an important cellular energy source for short term ATP needs prior to oxidative phosphorylation.
Supplemental creatine may have an energy-generating action during anaerobic exercise and may also have neuroprotective and cardioprotective actions.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
Creatine, creatine kinase and phosphocreatine make up an intricate cellular enegy buffering and transport system connecting sites of energy production in the mitochondria with sites of energy consumption. CK is a key enzyme in involved in cellular energy homeostasis. It reversibly catalyzes the transfer of the high-energy phosphate bond in PCr to adenosine diphosphate (ADP) to form adenosine triphosphate (ATP), and it catalyzes the transfer of the high-energy phosphate bond in ATP to creatine to form PCr. During periods of intense exercise and skeletal muscle contraction, bioenergetic metabolism switches from one in which oxidative phosphorylation is the major pathway of ATP production to one in which so-called anaerobic glycolysis becomes dominant.
Medical Economics Co; Physicians Desk Reference for Nutritional Supplements 1st ed p.115 (2001)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
